Piper Sandler raised the firm’s price target on AbbVie (ABBV) to $284 from $231 and keeps an Overweight rating on the shares. With settlements in place between generic filers and AbbVie on Rinvoq, coupled with strong performance across the commercial portfolio, the firm continues to argue for further multiple expansion. Piper continues to view AbbVie as one of the very few among its peers that offers an enviable trifecta of significant organic top-line/EBITDA growth, asset durability, and vast business development/M&A bandwidth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- AbbVie price target raised to $250 from $245 at Cantor Fitzgerald
- Aldeyra price target raised to $7 from $6 at Jefferies
- AbbVie reports ‘positive’ results from Phase 2 ELATE trial
- Wells says Biktarvy patent settlement ‘big deal’ for Gilead at, $6-$12 upside